Table 1.

Baseline participant characteristics

Participant characteristics	Non atopic (n = 54)	Atopic (n = 23)	p
Age, mean (SD)	69.3 (7.1)	69.7 (7.1)	0.86
Gender, % male	63	57	0.60
Race, (%)
Caucasian	89	83	0.71
Black/African American	9	13
Other	2	4
Education, (%)
< High School	19	22	0.63
High School	24	9
Some College	30	39
Bachelor’s Degree	13	13
At least some Graduate School	15	17
Smoking History, mean (SD)
Pack Years	56.8 (28.4)	60.7 (31.0)	0.60
Last Cigarette (Years Since)	13.0 (9.7)	13.4 (8.0)	0.85
Baseline Health Status
Post Bronchodilator FEV1% predicted, mean (SD)	52.4 (16.11)	51.9 (17.29)	0.89
Pre FEV1/FVC	0.50 (0.10)	0.52 (0.10)	0.45
Post FEV1/FVC	0.51 (0.10)	0.54 (0.11)	0.28
Bronchodilator reversibility, (%)	31.5	30.4	0.93
Chronic Bronchitis (%)	39	35	0.73
Emphysema (%)	57	70	0.32
SGRQ, mean (SD)	38.6 (17.6)	42.0 (20.7)	0.47
MMRC, mean (SD)	2.6 (1.0)	2.5 (1.2)	0.63
Medication list, (%)
Long acting beta agonist (LABA)	8	4	0.61
Inhaled Corticosteroids (ICS)	19	5	0.12
ICS/LABA combination	44	65	0.10
Long acting muscarinic antagonist	37	43	0.60
Nasal steroids	6	9	0.61
Leukotriene modifiers	8	9	0.88
Theophylline	2	9	0.16
Antihistamine	2	9	0.16
Comorbidities, (%)
Congestive heart failure	6	9	0.61
Diabetes	19	26	0.45
Cancer	19	22	0.74
Myocardial infarction	11	22	0.22
Hypertension	59	61	0.90
Kidney disease	2	0	0.51

Please note some of the data from the above table were previously published in a manuscript from the CODE cohort [5].

BCSS = Breathlessness, Cough, and Sputum Scale.

SGRQ = St. George’s Respiratory Questionnaire.

MMRC = Modified Medical Research Council.

FEV₁ = Forced expiratory volume in 1 second.

FVC = Forced vital capacity.

SD = Standard deviation.